Skip to main content
Contact Us
Subscribe
E-Edition
45°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
32.12
-0.30 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunocore Holdings Plc ADR
< Previous
1
2
3
4
5
6
Next >
3 Fast-Growing Stocks Analysts See Doubling in Price
November 11, 2024
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.
Via
MarketBeat
Navigating 8 Analyst Ratings For Immunocore Hldgs
November 11, 2024
Via
Benzinga
Immunocore to present at upcoming investor conferences
November 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports third quarter financial results and provides a business update
November 06, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs
October 24, 2024
Via
Benzinga
Analyst Ratings For Immunocore Hldgs
October 07, 2024
Via
Benzinga
Analyst Expectations For Immunocore Hldgs's Future
September 17, 2024
Via
Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
September 17, 2024
Via
Benzinga
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the 2024 Cantor Global Healthcare Conference
September 12, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces transition of Chief Financial Officer
August 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
The Latest Analyst Ratings For Immunocore Hldgs
August 28, 2024
Via
Benzinga
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
August 09, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
July 10, 2024
Via
Benzinga
Immunocore reports second quarter financial results and provides a business update
August 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
3 Small-Cap Stocks with Significant Growth Potential
August 06, 2024
As sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love.
Via
InvestorPlace
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
August 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
June 18, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Analyst Expectations For Immunocore Hldgs's Future
May 24, 2024
Via
Benzinga
Where Immunocore Hldgs Stands With Analysts
April 29, 2024
Via
Benzinga
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
April 11, 2024
Via
Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
IMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Immunocore reports first quarter financial results and provides a business update
May 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.